VYNDAQEL® OR VYNDAMAX™ (tafamidis meglumine or tafamidis) Indications and Usage
1. INDICATIONS AND USAGE
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
- I accept that Pfizer will validate that I am a health care professional.